Has Erik Wissner, MD received payments from drug or device companies?

Yes. Drug and device makers reported $67,352 in general payments to Erik Wissner, MD across 162 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Erik Wissner, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Erik Wissner, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Erik Wissner, MD

Cardiovascular Disease · Seattle, WANPI 1508849340

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (55.5%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. Medtronic accounts for 80.3% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2019 at $36,688 and has fallen 99.9% since, to $42 in 2025. Among cardiovascular disease clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$67,352in general payments, 2019–2025

Across 162 payments — averaging $415.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Medtronic$54K
Cardiofocus, Inc.$10K
Boston Scientific$3K
Abbott$116
Biosense Webster, Inc.$49
Stereotaxis Inc$49
plus $55 from 2 others

$57,781in research payments, 2019–2025

Across 26 payments — averaging $2222.36 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Novartis$29K
Abbott$10K
Boston Scientific$8K
Stereotaxis Inc$7K
Cardiofocus, Inc.$3K
Medtronic$475

What the payments were for

Consulting fees$12,60019%
Speaking & faculty fees$37,40056%
Travel & lodging$12,73019%
Food & beverage$4,6227%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Medtronic(2 entities)	104	$54,079
Cardiofocus, Inc.	10	$10,356
Boston Scientific	36	$2,649
Abbott	5	$116
Biosense Webster, Inc.	3	$49
Stereotaxis Inc	1	$49
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)	2	$33
Biotronik NRO, Inc.	1	$22

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$67,352 in reported general payments places this provider in the 95th percentile of 370 cardiovascular disease providers in Washington.

See all cardiovascular disease providers in Washington →

Medicare billing

Part B allowed, 2024

$158,964

Medicare patients

515

Services billed

1,507

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
EliquisApixaban	214	$293,699
XareltoRivaroxaban	47	$60,256
JardianceEmpagliflozin	12	$17,072
Metoprolol Succinate	248	$3,498
Flecainide Acetate	43	$1,419
Omeprazole	82	$944
Amiodarone Hcl	58	$683
Cartia XtDiltiazem Hcl	18	$634
Atorvastatin Calcium	58	$632
Diltiazem 24hr Er (Cd)Diltiazem Hcl	27	$547
Amlodipine Besylate	57	$409
SotalolSotalol Hcl	15	$396
Losartan Potassium	51	$372
Lisinopril	39	$362
Rosuvastatin Calcium	18	$319

Paid to pharmacies, not to this prescriber.

Other cardiovascular disease in Seattle

Mariko HarperSeattle$246K
Gary OppenheimSeattle$153K
Kelley BranchSeattle$103K
Younghoon KwonSeattle$66K
Aron BenderSeattle$60K
Vidhushei YogeswaranSeattle$55K
Santanu BiswasSeattle$30K
Bhanu GuptaSeattle$27K
Michael LongoSeattle$22K
Oana PetrescuSeattle$13K

See the full list for Washington →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →